After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, ROIV falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Roivant Sciences Ltd is $8.82B. A total of 8.59 million shares were traded on the day, compared to an average of 5.87M shares.
In the most recent transaction, Ramaswamy Vivek sold 1,195,000 shares of ROIV for 12.50 per share on Sep 03 ’25. After the transaction, the 10% Owner now owns 36,089,108 company shares. In a previous transaction on Sep 05 ’25, Ramaswamy Vivek sold 385,816 shares at 12.96 per share. ROIV shares that 10% Owner owns now total 35,508,359.
Among the insiders who sold shares, Ramaswamy Vivek disposed of 194,933 shares on Sep 04 ’25 at a per-share price of $12.92. This resulted in the 10% Owner holding 35,894,175 shares of ROIV after the transaction. In another insider transaction, Venker Eric sold 100,000 shares at $11.72 per share on Aug 20 ’25. Company shares held by the President & Immunovant CEO now total 1,653,585.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, ROIV has a high of $13.08 and a low of $8.73.
As of this writing, ROIV has an earnings estimate of -$0.31 per share for the current quarter. EPS was calculated based on a consensus of 4.0 estimates, with a high estimate of -$0.25 per share and a lower estimate of -$0.43. The company reported an EPS of -$0.3 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ROIV’s latest balance sheet shows that the firm has $2.06B in Cash & Short Term Investments as of fiscal 2022. There were $283.89M in debt and $184.37M in liabilities at the time. Its Book Value Per Share was $6.37, while its Total Shareholder’s Equity was $2.06B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ROIV is Buy with a score of 4.69.
